I've never traded "rights" before, so let me see if I have this right: What I would be purchasing tomorrow are phantom rights owned by Cell Pathways shareholders. These rights entitle Cell Pathway shareholders(pre-buyout) to sub-market prices on OSIP shares. Is that the jist of this and are these rights contingent on FDA approval of CP461?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.